# Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

> **NCT05190419** · PHASE2 · COMPLETED · sponsor: **UNION therapeutics** · enrollment: 202 (actual)

## Conditions studied

- Psoriasis
- Skin Diseases

## Interventions

- **DRUG:** Orismilast modified release tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05190419
- **Lead sponsor:** UNION therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2022-11-24
- **Final completion:** 2022-12-20
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190419, "Study to Assess the Efficacy and Safety of Orismilast in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05190419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*